|Application ||IHC-P, IF, WB, E|
|Calculated MW||19979 Da|
|Other Names||Anterior gradient protein 2 homolog, AG-2, hAG-2, HPC8, Secreted cement gland protein XAG-2 homolog, AGR2, AG2|
|Target/Specificity||This Anterior Gradient 2 (AGR2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 13-42 amino acids from the N-terminal region of human Anterior Gradient 2 (AGR2).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Anterior Gradient 2 (AGR2) Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells (By similarity). Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. Promotes cell adhesion (PubMed:23274113).|
|Cellular Location||Secreted. Endoplasmic reticulum|
|Tissue Location||Expressed strongly in trachea, lung, stomach, colon, prostate and small intestine. Expressed weakly in pituitary gland, salivary gland, mammary gland, bladder, appendix, ovary, fetal lung, uterus, pancreas, kidney, fetal kidney, testis, placenta, thyroid gland and in estrogen receptor (ER)-positive breast cancer cell lines.|
Provided below are standard protocols that you may find useful for product applications.
Anterior gradient 2 (AGR2) is known as a cancer cell marker specifically up-regulated in response to depletion of serum and oxygen. AGR2 has been identified as a tumor marker in primary and secondary cancer lesions, and as a marker for detection of circulating tumor cells (CTCs). Elevated levels of AGR2 are known to increase the metastatic potential of cancer cells, but conditions leading to increased expression of AGR2 are not well understood.
Zweitzig,D.R., Mol. Cell. Biochem. 306 (1-2), 255-260 (2007)
Zhang,Y., Prostate Cancer Prostatic Dis. 10 (3), 293-300 (2007)
Fletcher,G.C., Br. J. Cancer 88 (4), 579-585 (2003)